NCT02969200View on ClinicalTrials.gov

Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

December 9, 2016

Conditions
Fabry Disease
Interventions
DRUG

Enzyme replacement therapy

All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta

Trial Locations (1)

DK-2100

National University Hospital, Department of Medical Endocrinology, Copenhagen

All Listed Sponsors
lead

Ulla Feldt-Rasmussen

OTHER

NCT02969200 - Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance | Biotech Hunter | Biotech Hunter